Human interferon beta

Summary

Human interferon beta is an endogenous cytokine of the type I interferon family with antiviral, immunomodulatory, and antiproliferative properties. Recombinant forms (IFN-β-1a and IFN-β-1b) are approved for the treatment of relapsing forms of multiple sclerosis (MS). They reduce relapse rates, slow disability progression, and decrease MRI lesion burden. IFN-β-1a is glycosylated (produced in CHO cells) while IFN-β-1b is non-glycosylated (produced in E. coli) with a serine substitution at position 17.

Mechanism of Action

Binds to the type I interferon receptor (IFNAR1/IFNAR2) on cell surfaces, activating the JAK-STAT signaling pathway (JAK1 and TYK2), leading to transcription of interferon-stimulated genes (ISGs). This results in immunomodulatory, antiviral, and antiproliferative effects. In multiple sclerosis, reduces T-cell activation, decreases pro-inflammatory cytokine production, inhibits T-cell migration across the blood-brain barrier, and downregulates MHC class II expression.

Routes of Administration

Goals & Uses

• Reduction of relapse rate in relapsing-remitting multiple sclerosisDisease ModificationHigh
• Delay of disability progression in MSNeurological / AutoimmuneHigh
• Clinically isolated syndrome (CIS) — delay to clinically definite MSNeurological / AutoimmuneHigh
• Antiviral activityInfectious DiseaseModerate
• Reduction of MRI lesion burdenNeurological / AutoimmuneHigh

Contraindications

• Pregnancy (especially IFN-β-1b)ReproductiveModerate
• Decompensated hepatic diseaseHepaticHigh
• Severe depressive disorder with suicidal ideationPsychiatricHigh
• Hypersensitivity to natural or recombinant interferon beta or any excipientAllergy / ImmunologyHigh

Adverse Effects

• Hepatotoxicity / elevated liver enzymesHepaticCommon
• Injection site reactionsLocalCommon
• Hematological abnormalities (leukopenia, thrombocytopenia, anemia)HematologicalUncommon
• Flu-like symptoms (fever, chills, myalgia, fatigue)Systemic / ConstitutionalCommon
• Depression and suicidal ideationPsychiatricUncommon
• Neutralizing antibodies (NAbs)ImmunologicalCommon

Drug Interactions

• Myelosuppressive agentsModerate
• Immunosuppressants (e.g., corticosteroids)Low
• CYP450 substrates (e.g., warfarin, phenytoin)Low
• Hepatotoxic drugs (e.g., methotrexate, azathioprine, statins)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pre-existing severe psychiatric disordersPsychiatricRelative
• LactationReproductiveRelative
• Pediatric patients (<12 years)PediatricRelative

Regulatory Status

• European UnionApprovedApproved: Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis with active disease, Clinically isolated syndrome (CIS)Betaferon, Avonex, Rebif, and Extavia all hold EMA approval. Marketing authorizations granted from mid-1990s onward.
• United StatesApprovedApproved: Relapsing forms of multiple sclerosis (including RRMS, active SPMS, CIS), First MS disease-modifying therapy (IFN-β-1b, Betaseron, approved 1993)Avonex (IFN-β-1a IM) approved 1996; Rebif (IFN-β-1a SC) approved 2002; Extavia (IFN-β-1b SC) approved 2009. All require prescription.
• United KingdomApprovedApproved: Relapsing-remitting multiple sclerosis, Active secondary progressive multiple sclerosis, Clinically isolated syndromeMHRA-approved products include Avonex, Rebif, Betaferon, and Extavia. NICE guidelines support use within defined criteria.

IFN-β-1b (Betaseron/Betaferon) was the first disease-modifying therapy approved for MS (FDA, 1993). IFN-β-1a products (Avonex, Rebif) subsequently received approval. All are Schedule/prescription-only medicines across major jurisdictions.

Evidence & Sources

No sources recorded yet.